Home / Business and Economy / GSK Aims for £1.9B Savings by 2029

GSK Aims for £1.9B Savings by 2029

28 Jul

Summary

GSK aims for £1.9 billion in annual savings by 2029.
Savings will fund increased investment in the company's pipeline.
The strategy addresses revenue loss from an expiring HIV drug patent.

GSK Plc's chief executive officer has outlined an ambitious plan to achieve annual savings of £1.9 billion ($2.5 billion) by the year 2029. This initiative is crucial for the pharmaceutical giant as it prepares to navigate the financial implications of a major HIV medicine's patent expiry.

The substantial savings are earmarked to bolster GSK's investment in its research pipeline. This increased funding aims to develop new treatments and ensure the company maintains a robust portfolio of innovative medicines. The strategic move is designed to offset the anticipated decline in revenue stemming from the loss of exclusivity on a significant HIV drug.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.